Table 1.

Parameters for cost-effectiveness model

Variable	Value	Range		Distribution	Source
		Minimum	Maximum
Transition probabilities
Pembrolizumab
Progression from stable state	0.281	0.225	0.337	Beta	14
Death from stable state	0.079	0.063	0.095	Beta	14
Mortality after progression	0.104	0.083	0.125	Beta	14
Standard chemotherapy
Progression from stable state	0.260	0.208	0.312	Beta	14
Death from stable state	0.096	0.076	0.115	Beta	14
Mortality after progression	0.140	0.112	0.168	Beta	14
Utilities
Stable state	0.650	0.500	1.000	Beta	26
Progressive state	0.520	0.200	0.700	Beta	26
Cost
Pembrolizumab	5421	4337	6506	Gamma	Calculated
Standard first	1439	1151	1727	Gamma	Calculated
Standard	1253	1002	1503	Gamma	Calculated
Administration	13	10	15	Gamma	Calculated
Test	154	123	185	Gamma	Calculated
Time cost	750	600	900	Gamma	Calculated
Severe adverse events
Pembrolizumab	1227	981	1472	Gamma	Calculated
Standard	5855	4684	7027	Gamma	Calculated
Cancer progression	2555	1677	3620	Gamma	21
Best supportive care	157.6	126.1	191.5	Gamma	20
Terminal cancer care	2039.4	1631.5	2447.3	Gamma	19